Current Neuropharmacology, 2023, 21, 2020-2029

COMMENTARY



Bidirectional Communication Between Microglia and Astrocytes in Neuroinflammation



Anup Bhusal^{1,2,#}, Ruqayya Afridi^{1,2,#}, Won-Ha Lee^{3,4} and Kyoungho Suk^{1,2,4,*}

¹Department of Pharmacology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea; ²Department of Biomedical Sciences, School of Medicine, BK21 Plus KNU Creative BioResearch Group, Kyungpook National University, Daegu, Republic of Korea; ³School of Life Sciences, BK21 Plus KNU Creative BioResearch Group, Kyungpook National University, Daegu 41566, Republic of Korea; ⁴Brain Science and Engineering Institute, Kyungpook National University, Daegu 41944, Republic of Korea

ARTICLE HISTORY

Received: August 17, 2022 Revised: October 12, 2022 Accepted: November 11, 2022

DOI: 10.2174/1570159X21666221129121715



Abstract: Neuroinflammation is a common feature of diverse nervous system pathologies. In many instances, it begins at an early stage of the disease, paving the way for further exacerbations. The main drivers of neuroinflammation are brain-resident glial cells, such as microglia and astrocytes. Microglia are the primary responders to any insult to the brain parenchyma, translating the signals into diverse molecules. These molecules derived from microglia can regulate the stimuli-dependent reactivity of astrocytes. Once activated, astrocytes in turn, can control microglia phenotypes. Recent evidence indicates that the crosstalk between these glial cells plays an important role in delaying or accelerating neuroinflammation and overall disease progression. To date, various molecules have been recognized as key mediators of the bidirectional communication between microglia and astrocytes. The current review aims to discuss the novel molecules identified recently, which play a critical role in interglial crosstalk, highlighting their therapeutic potential.

Keywords: Microglia, astrocytes, crosstalk, neuroinflammation, glia, central nervous system.

1. INTRODUCTION

Neuroinflammation has emerged as a critical regulator of many central nervous system (CNS) pathologies, and it is mediated by complex molecular crosstalk between microglia and astrocytes. Microglia and astrocytes are dynamic glial cells that respond to all CNS insults and undergo context-dependent morphological and functional changes [1]. Both cell types conduct continuous interaction to regulate the CNS microenvironment in health and disease [2]. Following insults to the brain tissue, microglia undergo extensive transcriptional reprogramming, releasing a plethora of cytokines and inflammatory mediators. These secreted molecules act as messengers to facilitate communication between microglia and astrocytes [3]. Reactive astrocytes can regulate microglial functions in a similar manner (Fig. 1).

Bidirectional communication between microglia and astrocytes determines their functional outcomes and regulates neuronal activity. Identifying putative molecules in their

cellular crosstalk may provide better therapeutic options for many neurological disorders. To date, various molecules involved in interglial crosstalk have been identified and extensively reviewed by Jha *et al.* [2]. The current commentary briefly discusses the extant literature on the major molecules involved in reciprocal communication between microglia and astrocytes.

2. MICROGLIA-DERIVED MOLECULES REGULATING ASTROCYTES

Microglia-derived molecules play a definitive role in determining astrocytic function and fate in both health and disease. Several secreted molecules, including cytokines, neurotransmitters, growth factors, and microRNAs, are reportedly involved in the regulation of astrocyte activities. Recently, axon guidance molecules (AGMs) have emerged as key players in the regulation of microglia-astrocyte crosstalk. Microglia-derived molecules may confer beneficial functions or induce pathogenic activity in astrocytes in a context-dependent manner (Table 1) [4-18].

Following changes in the brain microenvironment during pathological conditions, microglia activate inflammatory signaling pathways, including classical nuclear factor kappa

^{*}Address correspondence to this author at the Department of Pharmacology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea; Tel: +82-53-420-4835; Fax: +82-53-256-1566; E-mail: ksuk@knu.ac.kr

^{*}These authors contributed equally to this work.




Fig. (1). Bidirectional molecular crosstalk between microglia and astrocytes under neuroinflammatory conditions. Microglia and astrocytes secrete context-dependent molecules to regulate each other's roles in various disease conditions. Microglia can induce the antiinflammatory/neuroprotective functions of astrocytes in a disease-stage-specific manner by releasing IGF-1, TGF-α, plexin-B2, and miR-124. Conversely, increased inflammatory signaling such as NF-κB, MAPK, PI3K, and Akt can lead to the release of pro-inflammatory mediators, including TNF-α, IL-1α, IL-1β, IL-18, C1q, ROS, Sema4D, EphrinB3, TGF-β, and VEGF-B, from microglia that can potentiate the neuroinflammatory/neurotoxic activities of astrocytes. Similarly, increased NF-κB, iNOS, GSTs, and Akt in astrocytes cause the release of various molecules, such as TNF-α, IL-1β, IL-15, CCL2, C3, GM-CSF, NO, fibronectin, SFRP1, Wnt5a, C8γ, miR-137, IL-3, IL-33, and glutamate, that act on microglia to regulate their functions in health and disease. SFRP1, secreted frizzled-related protein 1; IL, interleukin; CCL2, chemokine (C-C motif) ligand 2; GM-CSF, granulocyte-macrophage colony-stimulating factor; TNF, tumor necrosis factor; NO, nitric oxide; ROS, reactive oxygen species; CRAMP, cathelicidin-related antimicrobial peptide; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; MAPK, mitogen-activated protein kinase; PI3K, phosphoinositide 3-kinases; Akt, protein kinase B; GSTs, glutathione Stransferases; iNOS, inducible nitric oxide synthase; C3, complement component 3; C8γ, complement component 8 gamma; Wnt5a, winglesstype MMTV integration site family member 5a; Sema4D, semaphorin-4D; TGF, transforming growth factor; C1q, complement component 1 q; VEGF-B, vascular growth factor-beta; miR, microRNA; IGF-1, insulin-like growth factor 1. (A higher resolution/colour version of this figure is available in the electronic copy of the article).

B (NF-κB), mitogen-activated protein kinase, and phosphoinositide 3-kinase/protein kinase B, leading to increased secretion of pro-inflammatory mediators, such as interleukin 1 beta (IL-1β), tumor necrosis factor-alpha (TNF-α), and complement component 1q (C1q). Accumulating evidence has identified microglia-derived inflammatory mediators as triggers for inducing the neurotoxic phenotype of astrocytes in various disease states [5-8, 10, 12-14, 19]. Limiting microglial inflammatory signaling has been shown to inhibit astrocytic neurotoxicity.

A recent study identified microglia-derived AGMs' crucial role in potentiating astrocyte inflammatory activities in an experimental autoimmune encephalomyelitis (EAE) model [4]. The increased release of two AGMs, including semaphorin 4D (Sema4D) and Ephrin-B3, from microglia coincided with disease severity. Increased release of Sema4D and Ephrin-B3 from microglia activates astrocytic Plexin-B2 and EphB3 receptors, inducing neurotoxic astrocytes. Viralmediated perturbation of these interaction pathways decreased disease severity in the EAE model, confirming the regulatory role of microglia in controlling astrocytic responses.

Rothhammer et al. provided an elegant example of the explicit control of astrocytic responses by microglia in EAE [11]. Vascular endothelial growth factor B (VEGF-B) released from inflammatory microglia induces neurotoxic astrocytes by interacting with its receptor, Fms-related receptor tyrosine kinase 1 (FLT1), in EAE, exacerbating ongoing neuroinflammatory signaling. Conversely, the release of transforming growth factor alpha (TGF-α) from microglia enhances the neuroprotective activities of astrocytes, leading to disease amelioration. Furthermore, VEGF-B-FLT1 upregulation and TGF-α-ErbB1 downregulation were found in patients with multiple sclerosis, corroborating findings observed in animal models.

Table 1. Microglia-secreted molecules regulating the fate of astrocytes.

Phenotype	Category	Molecules	Implications	References
Pro-inflammatory/ neurotoxic	AGMs	EphrinB3 Sema4D	↑Proinflammatory cytokines ↑EAE-associated pathology ↑NOS2 and IL-1β	[4]
		IL-18	↑NF-κB signaling ↑Migraine pain	[5]
		IL-1β	↑NF-κB signaling	[6]
	Cytokines	TNF-α	↑NF-κB signaling ↑Post-surgical pain ↑Epileptogenesis ↑Disease burden in AD and PD	[6-9]
		IL-1α	↑Post-surgical pain ↑Epileptogenesis ↑Neurodegeneration in PD	[7-9]
	Complement	C1q	↑Post-surgical pain ↑Neurodegeneration in PD	[7, 9, 10]
		VEGF-B	↑EAE-associated pathology	[11]
	Growth factor	TGF-β1	↑Scar-associated pathology	[12]
	Vesicles/exosomes containing miRNA	miR-145-5p	VAstrocyte proliferation	[13]
	Pro-inflammatory mediators	ROS	↑Pain hypersensitivity	[14]
	Organelle	Damaged mitochondria	↑Neurodegeneration in ALS, AD, and HD	[15]
Anti-inflammatory/ neuroprotective	0 4.5.4	IGF-1	↑Axonal regeneration and functional recovery	[16]
	Growth factor	TGF-α	↓ EAE pathology	[11]
	AGMs	Plexin-B2	↑Wound healing	[17]
	Vesicles containing miRNA	miR-124	↑Recovery after stroke	[18]

Abbreviations: AGMs, axon guidance molecules; Sema4D, semaphorin-4D; IL, interleukin; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; TNF, tumor necrosis factor; TGF, transforming growth factor; C1q, complement component 1 q; NOS, nitric oxide synthase; VEGF-B, vascular growth factor beta; miR, microRNA; IGF-1, insulin-like growth factor 1; EAE, experimental autoimmune encephalomyelitis; AD, Alzheimer's disease; ALS, amyotrophic lateral sclerosis; HD, Huntington's disease; PD, Parkinson's disease.

Innate immune responses generated by brain-resident immune cells appear early in all neurodegenerative diseases, contributing to neurodegeneration. Previous reports have identified microglia as propagators of the inflammatory response induced by mutant protein aggregates in various neurodegenerative diseases. This notion has been confirmed in many in-vitro studies. The conditioned media from amyloidbeta (Aβ)-treated microglial cell cultures induced inflammatory signaling in astrocytes, while AB alone did not affect astrocyte reactivity [6, 10]. The transfer of conditioned media from α-synuclein preformed fibril-treated microglial cultures to astrocytes increased the transcripts of inflammatory genes [9]. In animal models of sporadic Parkinson's disease (PD), the blockade of microglial inflammatory phenotype suppressed the induction of astrocytic neurotoxicity and resultant neurodegeneration [9]. In addition to classic inducers of inflammatory astrocytes, including IL-1α, IL-1β, TNF-α, and C1q, increased mitochondrial damage in microglial cells also triggered the neurotoxic reactivity of astrocytes in neurodegenerative diseases [15]. Increased mitochondrial fission in inflammatory microglia led to an extracellular release of dysfunctional mitochondria, which acted as an inflammatory signal, resulting in the induction of neurotoxic astrocytes [15].

Adequate glial responses play key roles in disease progression and mitigation. Microglia-derived molecules can also skew astrocytic reactivity toward beneficial roles and can aid in halting disease progression [18]. Insulin-like growth factor-1 is an immunomodulatory molecule released by microglia, which increases astrocyte migration and subsequent scar formation in spinal cord injury [16]. Scarforming astrocytes are crucial for limiting the infiltration of peripheral immune cells and for dampening disease progression. Small vesicles enriched in miR-124 secreted from microglia also potentiated the beneficial function of astrocytes in an ischemic brain injury model. Initially regarded as AGM, plexins are now known to induce a plethora of immune functions in a context-dependent manner. Various ligands can activate plexin-mediated signaling, regulating cellular interactions. Contrasting findings have been recently reported regarding plexin-mediated immune effects in the CNS [20-22]. Zhou et al. found a protective role of microglial plexin-B2-signalling in regulating the physical interaction

between microglia and astrocytes in an animal model of spinal cord injury [17]. Tissue repair following spinal cord injury depends on the proper arrangement of distinct cell types surrounding the injury sites, and microglial plexin-B2 aided in confining the territories of microglia and astrocytes. Plexin-B2 signaling in microglia regulates the spatial segregation of microglia and astrocytes around the injury site and determines the efficiency of wound healing [17].

Microglial cells are not homogenous populations and transit to many other phenotypes in a context-dependent manner. In addition, CNS is also home to numerous other types of myeloid cells with distinct localization, including perivascular, choroid plexus, and meningeal macrophages/dendritic cells [23]. Microglia are the major myeloid cells residing in the healthy brain parenchyma, hence named brain macrophages. In various neuroinflammatory conditions, bone marrow-derived peripheral myeloid cells are also found to infiltrate the brain tissue. Microglia share their surface markers with other myeloid cell types, making it difficult to identify brain-resident microglial cells in neuroinflammatory

conditions [24, 25]. The heterogeneity and complexity of CNS myeloid cell dynamics linked to neuroinflammation require better tools to characterize the contribution of specific cell types to disease pathology. Further investigations are necessary to dissect the molecular, cellular, and phenotypic heterogeneity of myeloid cells in various neuroinflammatory diseases.

3. ASTROCYTE-DERIVED MOLECULES REGULAT-ING MICROGLIAL FUNCTION IN HEALTH AND DISEASE

As discussed above, various studies have reported that microglia are upstream regulators of astrocyte functions. However, it is also important to consider the reciprocal regulation of microglia by astrocytes [2]. In this regard, various cytokines and chemokines, such as IL-1β, IL-10, IL-15, TNF-α, nitric oxide, and chemokine ligand 2 (CCL2) are also secreted by astrocytes, which act on microglia to regulate their functions [2, 26-31] (Table 2).

Table 2. Astrocyte-derived molecules regulating microglial function in health and disease.

Phenotype	Category	Molecules	Implications	References
Pro-inflammatory/ neurotoxic	ECM	Fibronectin	↑ TNF-α production ↑ Disease burden in SCI	[32]
	Growth modulators	SFRP1	↑HIF, NF-κB - Sustain a chronic inflammation in EAE	[33]
		Wnt5a	↑ CD68 ↑ Microglia proliferation ↑ Disease burden in ALS	[34]
	Cytokines	IL-15	↑ CD86, IL-1β, and TNF-α production ↑ Brain injury following ICH	[30]
		IL-1β	↑ M1 polarization ↑ Neuroinflammation in 1,2-DCE-intoxicated mice	[31]
		TNF-α	↑ M1 Polarization ↑ Neuroinflammation in 1,2-DCE-intoxicated mice ↑ Disruption in risk assessment behavior	[29, 31]
		CCL2	↑ Microglia activation ↑ IL-1β production ↑ Neuronal apoptosis ↑ Disease burden in SCI ↑ Neuroinflammation in LPS-injected mice	[27, 35]
		GM-CSF	↑ Microglia activation ↑ Neuroinflammation in LPS-injected mice	[35]
	Complement	С3	↑Neuroinflammation ↑Disease pathology in neuromyelitis optica, Alzheimer's disease, epilepsy, depression, hydrocephalus, white matter injury, and prion disease	[36-43]
	Cathelicidins	CRAMP/ LL-37	↑Neuroinflammation ↑Disease burden in EAE	[44]
	Gliotransmitter	Glutamate	↑Microglia expansion and reactivity ↑Neuroinflammation ↑Disruption in risk assessment behavior	[29]

Phenotype	Category	Molecules	Implications	References
-	Pro-inflammatory mediators	NO	↑ M1 polarization ↑ Neuroinflammation in 1,2-DCE-intoxicated mice	[31]
Anti-inflammatory/ neuroprotective	Growth modulators	Wnt5a	↑ IL-6, CD206, CD163 ↑ Microglia proliferation - Disease onset delayed in ALS	[34]
	Cytokines	IL-3	↑ Motility of microglia ↑ Clearance of Aβ and tau aggregates -Restrict AD progression and cognitive decline	[45]
		IL-33	↑ Synapse engulfment -Improved synaptic pruning -Supports microglial metabolic adaptation and phagocytic function	[46, 47]
	Complement	С8ү	-Antagonizes the pro-inflammatory action of S1P in microglia VInflammation -Therapeutic containment of neuroinflammation in AD	[48]
	Vesicles/exosomes containing miRNA	miR-137	-Promote M2 polarization of microglia -Increase cell viability and attenuate apoptosis following OGD/R injury	[49]
		miR-873a-5p	 ↓ NF-κB signaling ↓ Inflammation -Attenuate neurological deficits following TBI 	[50]
	Nanotubes		↑ Degradation of αSYN and Aβ aggregates	[51]

Abbreviations: ECM, extracellular matrix; SCI, spinal cord injury; SFRP1, secreted frizzled-related protein 1; Wnt5a, wingless-type MMTV integration site family member 5a; IL, interleukin; ICH, intracerebral hemorrhage; CCL2, chemokine (C-C motif) ligand 2; GM-CSF, granulocyte-macrophage colony-stimulating factor; TNF, tumor necrosis factor; NO, nitric oxide; HIF, hypoxia-inducible factor; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; C3, complement component 3; C8γ, complement component 8 gamma; CRAMP, cathelicidin-related antimicrobial peptide; LL-37, leucine leucine 37; CD, cluster of differentiation; S1P, sphingosine-1-phosphate; ALS, amyotrophic lateral sclerosis; αSYN, alpha-synuclein; Aβ, amyloid beta; TBI, traumatic brain injury; OGD/R, oxygen-glucose deprivation/reperfusion; AD, Alzheimer's disease; DCE, dichloroethane; EAE, experimental autoimmune encephalomyelitis; LPS, lipopolysaccharide.

Recent studies have further reported other molecules that play key roles in this nexus. Our laboratory and others have identified complement components, such as C3 and C8γ, which are primarily expressed by astrocytes and specifically bind to their receptors on microglial cells [37, 48, 52]. Activated astrocytes produce complement protein C3, which is cleaved to produce C3a and C3b. C3a then binds to the C3aR receptor on microglia, promoting their activation and C1q production, thereby causing local injury to neurons [38, 43, 53]. Based on this finding, various other groups have exploited this pathway to study astrocyte-microglia interactions in status epilepticus [40], hydrocephalus [39], depression [36], white matter injury [41], and prion disease [42].

Cathelicidins are a group of molecules with antimicrobial function and are part of the innate immune response [54]. Several studies have reported that mouse cathelicidin-related antimicrobial peptide (CRAMP) and its human homolog cathelicidin (LL-37) play an important role in a variety of neuroinflammatory conditions [55-61]. In a recent study, Bhusal et al. identified the role of CRAMP as a mediator of astrocyte-microglia crosstalk in EAE or multiple sclerosis [44]. At the molecular level, they reported that CRAMP, which is primarily expressed by astrocytes, potentiates the IFN-γ-induced STAT3 signaling pathway in microglia via formyl peptide receptors. In line with this, mice lacking cathelicidin showed a lower incidence of EAE with a reduction in T cell-mediated IFN-y production [62]. Overall, these studies have unleashed the previously unidentified role of CRAMP in astrocyte-microglia communication.

Other mechanisms by which astrocytes regulate microglial functions during neuroinflammation involve the secretion of various proteins, such as fibronectin, Wnt5a, and secreted frizzled-related protein 1 (SFRP1) [32, 33]. In particular, SFRP1 expressed by astrocytes during neuroinflammation led to the transcription of the downstream targets of hypoxia-inducible factor and NF-κB in microglial cells, promoting their activation [33]. Other studies have found that NF-κB activation in astrocytes under various conditions causes the expression and/or release of CCL2, Wnt5a, and granulocyte-macrophage colony-stimulating factor (GM-CSF), which leads to the activation and expansion of microglia cells [34, 35, 63]. Specifically, Baumann and colleagues uncovered a significant role of the time-dependent regulation of NF-κB in astrocytes, which ultimately determines the fate of microglia to have either protective or detrimental function. In their study, IKK2/NF-κB was overexpressed in astrocytes of the SOD1 (G39A) mice, an amyotrophic lateral sclerosis (ALS) animal model. To their surprise, SOD1/IKK2 mice displayed delayed onset of the disease but with increased severity as the disease progressed. They have reported that NF-κB activation in astrocytes led to significant upregulation of Wnt5a, which acted on microglia to increase their proliferation, delaying the presymptomatic phase of ALS, but greatly increasing the severity of the symptomatic stage [34, 64]. Furthermore, another study has shown that secretome obtained from cortical astrocytes of mSOD1 mice upregulates the expression of iNOS and Tnf genes in microglia [65]. These findings suggest that astrocyte-microglia crosstalk

might regulate the overall inflammatory responses in neurodegenerative diseases such as ALS.

Small extracellular vesicles (sEVs) released from cells play a key role in cellular communication by transporting RNA, proteins, and bioactive lipids between cells [66]. Astrocytes can produce and export these sEV containing proteins and RNAs that affect different functions in target cells [67]. In the study by Rong et al., astrocytes were found to release sEVs encapsulating CCL2 during spinal cord injury [27]. Immunostaining analysis showed that CCR2, the main receptor for CCL2, was expressed predominantly by microglia and neuronal cells. They found that astrocytic sEVs containing CCL2 were transported to microglia and neuronal cells; CCL2 binding to CCR2 resulted in microglial activation. The activated microglia released IL-1\beta that further acted on the neurons aggravating neuronal apoptosis [27]. These results support that sEVs can be a potential mediator of astrocyte-microglia communication during neuroinflamma-

The astrocytic regulation of microglial function has also been implicated in homeostatic and anti-inflammatory conditions. Vainchtein et al. found that IL-33 produced by astrocytes regulated microglial synapse engulfment in the developing brain, suggesting the important role of interglial crosstalk in the sculpting of neural synapses and shaping of neural circuits [47]. Another group supported this finding; they found that astrocyte-microglia communication mediated by the IL-33-suppression of tumorigenicity (ST) 2-AKT pathway helped microglia for metabolic adaptation and phagocytic function during early development [46]. McAlpine et al. recently investigated the role of astrocyte-microglia interaction in the clearance of AB and the prevention of cognitive decline in the mouse model of Alzheimer's disease (AD). They found that astrocyte-specific IL-3 acts on microglial IL-3Rα receptors endowing them with enhanced motility and the capacity to clear amyloid plaques [45]. Recently, Kim et al. found that C8y, primarily expressed by astrocytes under AD and other neuroinflammatory conditions, interacts with the sphingosine-1-phosphate (S1P) receptor of microglia to antagonize the pro-inflammatory action of S1P [48]. They showed that shRNA-mediated knockdown of C8y inhibits glial hyperactivation, neuroinflammation, and cognitive decline in acute and chronic animal models of AD [48]. This was an interesting observation, as the majority of complement components are thought to be proinflammatory in nature.

Exosomes are a well-characterized subtype of EVs [68, 69]. In the study by Jing *et al.*, astrocytes were found to release exosomes containing miR-137 under the oxygenglucose deprivation/reperfusion conditions; these astrocytederived exosomes were taken up by microglia, causing their transformation to an anti-inflammatory M2 phenotype [49]. They further demonstrated that upregulation of miR-137 could significantly inhibit inositol polyphosphate 4-phosphatase expression, negatively regulating the PI3K/Akt pathway involved in cell survival and proliferation [49]. In another study, Long *et al.* have shown that astrocyte-derived exosomes containing miR-873a-5p attenuated microgliamediated neuroinflammation and improved neurological deficits following traumatic brain injury by inhibiting the NF-κB signaling pathway [50]. Similarly, other studies have

also proved the protective effects of astrocyte-derived exosomes in different neuroinflammatory conditions [70, 71]. Indeed, releasing exosomes may be one way for astrocytes to communicate with neighboring cells like microglia.

Apart from secreted molecules, state-of-the-art imaging techniques have identified the appearance of novel physical structures called nanotubes, forming direct physical contact between astrocytes and microglia for effective communication [51, 72]. These nanotubes allow for the intercellular transfer of aggregated proteins such as α -synuclein and A β from astrocytes to microglia, which are then broken down and removed from the culture [51]. The impairment of direct contact between astrocytes and microglia may further hamper the branching and migration of microglia [73]. Taken together, there appears to be an intimate astrocyte-microglia interaction at the functional and physical levels in both homeostatic and pathological states, thereby allowing them to govern and regulate each other's functions.

4. PERSPECTIVE AND FUTURE DIRECTIONS

The functions of glial cells are becoming more apparent with the identification of molecules they release. It has recently been shown that glial cells use these secretory molecules to functionally interact with other cell types. A better understanding of the complex microglia-astrocyte crosstalk could lead to the discovery of new diagnostic biomarkers and therapeutic targets for neuroinflammation and related disorders. As we summarized previously [2], most studies have focused on understanding well-known inflammatory mediators of cellular communication, such as cytokines, chemokines, and acute-phase proteins, which act through receptors in other cell types. Recently, other modes of communication involving enzymes, gliotransmitters, mitochondria, exosomes, AGMs, and cell-cell tunneling systems have been identified. Henceforth, we have begun to appreciate the importance of this microglia-astrocyte nexus. The development of advanced imaging systems, single-cell analysis techniques, transgenic animal models with cell-specific promoters, and elegant mouse genetics have further aided in expanding the understanding of this complex system.

Interglial crosstalk and targeted therapies based on this crosstalk are still in their infancy, and several issues remain to be further examined. One such difficulty is the presence of regional heterogeneity in the microglia and astrocytes under diverse conditions. This has led to the need to map these newly found glial molecules *in vivo* in real-time and to comprehend their relative roles within tissues in both homeostatic and pathological states.

Both microglia and astrocytes release TNF- α and IL-1 β , among others, to regulate each other's reactive states, which may ultimately lead to neurotoxicity [3, 29]. These proinflammatory cytokines are well known to induce apoptotic damage to brain cells, including neurons and oligodendrocytes [74]. Under these circumstances, microglia and astrocytes might also be susceptible to the toxic effects of proinflammatory mediators. The studies on this aspect are limited. However, the death-resistant nature of murine and human microglia and astrocytes, compared to neurons, has been reported in various *in-vitro* studies [75-78]. In addition, under *in-vivo* conditions, neuronal damage precedes glial dam-

age, implying that glial cells can withstand the damage even under a neuroinflammatory environment [79].

Another main challenge for glia interaction research is to handle and study a large number of new molecules being analyzed. This will require the combined effort of experts from several disciplines to pinpoint molecules and study their potential in neuroinflammation and neurodegenerative diseases. Furthermore, in many cases, the results have been oversimplified, and the use of non-physiological concentrations of glial molecules/proteins may provide some artifactual insights into the crosstalk. As a result, it is difficult to interpret the usefulness of the identified crosstalk. Moreover, a substantial translational gap between animal studies and clinical implications still exists. Nevertheless, exploration of glial molecules/proteins in human post-mortem tissues, cerebrospinal fluid and blood samples, as well as employment of human iPSC-derived glial cells [80, 81] and minimally invasive imaging techniques, can provide a functional readout for specific cells or molecules from a clinical perspective [80]. We believe that the clinical harnessing of glial molecules to diagnose and treat neurodegenerative diseases requires more basic research to better understand the molecular mechanisms underlying the crosstalk between them.

LIST OF ABBREVIATIONS

AGMs = Axon Guidance Molecules C1q = Complement Component 1 q

C3 = Complement Component 3

C8γ = Complement Component 8 Gamma CCL2 = Chemokine (C-C motif) Ligand 2

CNS = Central Nervous System

CRAMP = Cathelicidin-related Antimicrobial Peptide

CSF = Cerebrospinal Fluid

EAE = Experimental Autoimmune Encephalomyelitis

EphB3 = Ephrin B3 Receptor

ErbB1 = Erb-B1 Receptor Tyrosine Kinase

FLT1 = Fms-related Receptor Tyrosine Kinase 1

GM-CSF = Granulocyte-macrophage Colony-stimulating

Factor

HIF = Hypoxia-inducible Factor
IGF = Insulin-like Growth Factor

IL = Interleukin

iNOS = Inducible Nitric Oxide Synthase

LL-37 = Leucine Leucine-37

NF-κB = Nuclear Factor Kappa-light-chain-enhancer of

Activated B Cells

NO = Nitric Oxide

ROS = Reactive Oxygen Species S1P = Sphingosine-1-Phosphate

Sema4D = Semaphorin-4D

sEVs = Small Extracellular Vesicles

SFRP1 = Secreted Frizzled-related Protein 1

ST = Suppression of Tumorigenicity

TGF = Transforming Growth Factor

TNF = Tumor Necrosis Factor

VEGF = Vascular Endothelial Growth Factor

Wnt5a = Wingless-type MMTV Integration Site Family

Member 5a

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

This work was supported by a grant from the Basic Science Research Program through the National Research Foundation (NRF), which is funded by the Korean government (MSIP) (NRF-2017R1A5A2015391 and NRF-2020M3E5D9079764).

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES

[1] Nimmerjahn, A.; Kirchhoff, F.; Helmchen, F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science, 2005, 308(5726), 1314-1318. http://dx.doi.org/10.1126/science.1110647 PMID: 15831717

[2] Jha, M.K.; Jo, M.; Kim, J.H.; Suk, K. Microglia-astrocyte cross-talk: An intimate molecular conversation. *Neuroscientist*, 2019, 25(3), 227-240. http://dx.doi.org/10.1177/1073858418783959 PMID: 29931997

- [3] Liddelow, S.A.; Guttenplan, K.A.; Clarke, L.E.; Bennett, F.C.; Bohlen, C.J.; Schirmer, L.; Bennett, M.L.; Münch, A.E.; Chung, W.S.; Peterson, T.C.; Wilton, D.K.; Frouin, A.; Napier, B.A.; Panicker, N.; Kumar, M.; Buckwalter, M.S.; Rowitch, D.H.; Dawson, V.L.; Dawson, T.M.; Stevens, B.; Barres, B.A. Neurotoxic reactive astrocytes are induced by activated microglia. *Nature*, 2017, 541(7638), 481-487.
 - http://dx.doi.org/10.1038/nature21029 PMID: 28099414
- [4] Clark, I.C.; Gutiérrez-Vázquez, C.; Wheeler, M.A.; Li, Z.; Rothhammer, V.; Linnerbauer, M.; Sanmarco, L.M.; Guo, L.; Blain, M.; Zandee, S.E.J.; Chao, C.C.; Batterman, K.V.; Schwabenland, M.; Lotfy, P.; Tejeda-Velarde, A.; Hewson, P.; Manganeli Polonio, C.; Shultis, M.W.; Salem, Y.; Tjon, E.C.; Fonseca-Castro, P.H.; Borucki, D.M.; Alves de Lima, K.; Plasencia, A.; Abate, A.R.; Rosene, D.L.; Hodgetts, K.J.; Prinz, M.; Antel, J.P.; Prat, A.; Quintana, F.J. Barcoded viral tracing of single-cell interactions in central nervous system inflammation. Science, 2021, 372(6540), eabf1230.
 - http://dx.doi.org/10.1126/science.abf1230 PMID: 33888612
- [5] Gong, Q.; Lin, Y.; Lu, Z.; Xiao, Z. Microglia-astrocyte cross talk through IL-18/IL-18R signaling modulates migraine-like behavior in experimental models of migraine. *Neuroscience*, 2020, 451, 207-215. http://dx.doi.org/10.1016/j.neuroscience.2020.10.019 PMID: 33137409
- [6] Xie, L.; Zhang, N.; Zhang, Q.; Li, C.; Sandhu, A.F.; Iii, G.W.; Lin, S.; Lv, P.; Liu, Y.; Wu, Q.; Yu, S. Inflammatory factors and amyloid β-induced microglial polarization promote inflammatory crosstalk with astrocytes. *Aging (Albany NY)*, 2020, 12(22), 22538-22549.

http://dx.doi.org/10.18632/aging.103663 PMID: 33196457

- [7] Li, T.; Liu, T.; Chen, X.; Li, L.; Feng, M.; Zhang, Y.; Wan, L.; Zhang, C.; Yao, W. Microglia induce the transformation of A1/A2 reactive astrocytes via the CXCR7/PI3K/Akt pathway in chronic post-surgical pain. J. Neuroinflammation, 2020, 17(1), 211. http://dx.doi.org/10.1186/s12974-020-01891-5 PMID: 32665021
- [8] Sano, F.; Shigetomi, E.; Shinozaki, Y.; Tsuzukiyama, H.; Saito, K.; Mikoshiba, K.; Horiuchi, H.; Cheung, D.L.; Nabekura, J.; Sugita, K.; Aihara, M.; Koizumi, S. Reactive astrocyte-driven epileptogenesis is induced by microglia initially activated following status epilepticus. *JCI Insight*, 2021, 6(9), e135391. http://dx.doi.org/10.1172/jci.insight.135391 PMID: 33830944
- [9] Yun, S.P.; Kam, T.I.; Panicker, N.; Kim, S.; Oh, Y.; Park, J.S.; Kwon, S.H.; Park, Y.J.; Karuppagounder, S.S.; Park, H.; Kim, S.; Oh, N.; Kim, N.A.; Lee, S.; Brahmachari, S.; Mao, X.; Lee, J.H.; Kumar, M.; An, D.; Kang, S.U.; Lee, Y.; Lee, K.C.; Na, D.H.; Kim, D.; Lee, S.H.; Roschke, V.V.; Liddelow, S.A.; Mari, Z.; Barres, B.A.; Dawson, V.L.; Lee, S.; Dawson, T.M.; Ko, H.S. Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease. Nat. Med., 2018, 24(7), 931-938. http://dx.doi.org/10.1038/s41591-018-0051-5 PMID: 29892066
- [10] Xu, X.; Zhang, A.; Zhu, Y.; He, W.; Di, W.; Fang, Y.; Shi, X. MFG-E8 reverses microglial-induced neurotoxic astrocyte (A1) via NF-κB and PI3K-Akt pathways. J. Cell. Physiol., 2019, 234(1), 904-914. http://dx.doi.org/10.1002/jcp.26918 PMID: 30076715
- [11] Rothhammer, V.; Borucki, D.M.; Tjon, E.C.; Takenaka, M.C.; Chao, C.C.; Ardura-Fabregat, A.; de Lima, K.A.; Gutiérrez-Vázquez, C.; Hewson, P.; Staszewski, O.; Blain, M.; Healy, L.; Neziraj, T.; Borio, M.; Wheeler, M.; Dragin, L.L.; Laplaud, D.A.; Antel, J.; Alvarez, J.I.; Prinz, M.; Quintana, F.J. Microglial control of astrocytes in response to microbial metabolites. *Nature*, 2018, 557(7707), 724-728. http://dx.doi.org/10.1038/s41586-018-0119-x PMID: 29769726
- [12] Cheng, L.; Zheng, M-G.; Jing, J-H.; Yu, S-S.; Li, Z-Y.; Xu, X-Z.; Yao, F.; Luo, Y.; Liu, Y-C. M1-type microglia can induce astrocytes to deposit chondroitin sulfate proteoglycan after spinal cord injury. *Neural Regen. Res.*, 2022, 17(5), 1072-1079. http://dx.doi.org/10.4103/1673-5374.324858 PMID: 34558535
- [13] Ye, Y.; Hao, J.; Hong, Z.; Wu, T.; Ge, X.; Qian, B.; Chen, X.; Zhang, F. Downregulation of microRNA-145-5p in activated microglial exosomes promotes astrocyte proliferation by removal of Smad3 inhibition. *Neurochem. Res.*, 2022, 47(2), 382-393. http://dx.doi.org/10.1007/s11064-021-03446-3 PMID: 34623564
- [14] Peng, J.; Yi, M.H.; Jeong, H.; McEwan, P.P.; Zheng, J.; Wu, G.; Ganatra, S.; Ren, Y.; Richardson, J.R.; Oh, S.B.; Wu, L.J. The voltage-gated proton channel Hv1 promotes microglia-astrocyte communication and neuropathic pain after peripheral nerve injury. *Mol. Brain*, 2021, 14(1), 99. http://dx.doi.org/10.1186/s13041-021-00812-8 PMID: 34183051
- [15] Joshi, A.U.; Minhas, P.S.; Liddelow, S.A.; Haileselassie, B.; Andreasson, K.I.; Dorn, G.W., II; Mochly-Rosen, D. Fragmented mitochondria released from microglia trigger A1 astrocytic response and propagate inflammatory neurodegeneration. *Nat. Neurosci.*, 2019, 22(10), 1635-1648. http://dx.doi.org/10.1038/s41593-019-0486-0 PMID: 31551592
- [16] Bellver-Landete, V.; Bretheau, F.; Mailhot, B.; Vallières, N.; Lessard, M.; Janelle, M.E.; Vernoux, N.; Tremblay, M.È.; Fuehrmann, T.; Shoichet, M.S.; Lacroix, S. Microglia are an essential component of the neuroprotective scar that forms after spinal cord injury. *Nat. Commun.*, 2019, 10(1), 518. http://dx.doi.org/10.1038/s41467-019-08446-0 PMID: 30705270
- [17] Zhou, X.; Wahane, S.; Friedl, M.S.; Kluge, M.; Friedel, C.C.; Avrampou, K.; Zachariou, V.; Guo, L.; Zhang, B.; He, X.; Friedel, R.H.; Zou, H. Microglia and macrophages promote corralling, wound compaction and recovery after spinal cord injury via Plexin-B2. Nat. Neurosci., 2020, 23(3), 337-350. http://dx.doi.org/10.1038/s41593-020-0597-7 PMID: 32112058
- [18] Li, Z.; Song, Y.; He, T.; Wen, R.; Li, Y.; Chen, T.; Huang, S.; Wang, Y.; Tang, Y.; Shen, F.; Tian, H.L.; Yang, G.Y.; Zhang, Z. M2 microglial small extracellular vesicles reduce glial scar formation via the miR-124/STAT3 pathway after ischemic stroke in mice. Theranostics, 2021, 11(3), 1232-1248. http://dx.doi.org/10.7150/thno.48761 PMID: 33391532

- [19] Guo, X.; Kimura, A.; Namekata, K.; Harada, C.; Arai, N.; Takeda, K.; Ichijo, H.; Harada, T. ASK1 signaling regulates phase-specific glial interactions during neuroinflammation. *Proc. Natl. Acad. Sci. USA*, 2022, 119(6), e2103812119. http://dx.doi.org/10.1073/pnas.2103812119 PMID: 35101972
- [20] Paldy, E.; Simonetti, M.; Worzfeld, T.; Bali, K.K.; Vicuña, L.; Offermanns, S.; Kuner, R. Semaphorin 4C Plexin-B2 signaling in peripheral sensory neurons is pronociceptive in a model of inflammatory pain. *Nat. Commun.*, 2017, 8(1), 176. http://dx.doi.org/10.1038/s41467-017-00341-w PMID: 28765520
- [21] Southwell, A.L.; Franciosi, S.; Villanueva, E.B.; Xie, Y.; Winter, L.A.; Veeraraghavan, J.; Jonason, A.; Felczak, B.; Zhang, W.; Kovalik, V.; Waltl, S.; Hall, G.; Pouladi, M.A.; Smith, E.S.; Bowers, W.J.; Zauderer, M.; Hayden, M.R. Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease. *Neurobiol. Dis.*, 2015, 76, 46-56. http://dx.doi.org/10.1016/j.nbd.2015.01.002 PMID: 25662335
- [22] Zhou, Y.; Guo, S.; Botchway, B.O.A.; Zhang, Y.; Jin, T.; Liu, X. Muscone can improve spinal cord injury by activating the angiogenin/plexin-B2 Axis. *Mol. Neurobiol.*, 2022, 59(9), 5891-5901. http://dx.doi.org/10.1007/s12035-022-02948-7 PMID: 35809154
- [23] Jordão, M.J.C.; Sankowski, R.; Brendecke, S.M.; Sagar, ; Locatelli, G.; Tai, Y.H.; Tay, T.L.; Schramm, E.; Armbruster, S.; Hagemeyer, N.; Groß, O.; Mai, D.; Çiçek, Ö.; Falk, T.; Kerschensteiner, M.; Grün, D.; Prinz, M. Single-cell profiling identifies myeloid cell subsets with distinct fates during neuroinflammation. *Science*, 2019, 363(6425), eaat7554. http://dx.doi.org/10.1126/science.aat7554 PMID: 30679343
- [24] Ajami, B.; Samusik, N.; Wieghofer, P.; Ho, P.P.; Crotti, A.; Bjornson, Z.; Prinz, M.; Fantl, W.J.; Nolan, G.P.; Steinman, L. Single-cell mass cytometry reveals distinct populations of brain myeloid cells in mouse neuroinflammation and neurodegeneration models. *Nat. Neurosci.*, 2018, 21(4), 541-551. http://dx.doi.org/10.1038/s41593-018-0100-x PMID: 29507414
- [25] Goldmann, T.; Wieghofer, P.; Jordão, M.J.C.; Prutek, F.; Hagemeyer, N.; Frenzel, K.; Amann, L.; Staszewski, O.; Kierdorf, K.; Krueger, M.; Locatelli, G.; Hochgerner, H.; Zeiser, R.; Epelman, S.; Geissmann, F.; Priller, J.; Rossi, F.M.V.; Bechmann, I.; Kerschensteiner, M.; Linnarsson, S.; Jung, S.; Prinz, M. Origin, fate and dynamics of macrophages at central nervous system interfaces. *Nat. Immunol.*, 2016, 17(7), 797-805. http://dx.doi.org/10.1038/ni.3423 PMID: 27135602
- [26] O'Neil, S.M.; Hans, E.E.; Jiang, S.; Wangler, L.M.; Godbout, J.P. Astrocyte immunosenescence and deficits in interleukin 10 signaling in the aged brain disrupt the regulation of microglia following innate immune activation. *Glia*, 2022, 70(5), 913-934. http://dx.doi.org/10.1002/glia.24147 PMID: 35061297
- [27] Rong, Y.; Ji, C.; Wang, Z.; Ge, X.; Wang, J.; Ye, W.; Tang, P.; Jiang, D.; Fan, J.; Yin, G.; Liu, W.; Cai, W. Small extracellular vesicles encapsulating CCL2 from activated astrocytes induce microglial activation and neuronal apoptosis after traumatic spinal cord injury. *J. Neuroinflammation*, 2021, 18(1), 196. http://dx.doi.org/10.1186/s12974-021-02268-y PMID: 34511129
- [28] Kim, S.; Son, Y. Astrocytes stimulate microglial proliferation and M2 polarization in vitro through crosstalk between astrocytes and microglia. Int. J. Mol. Sci., 2021, 22(16), 8800. http://dx.doi.org/10.3390/ijms22168800 PMID: 34445510
- [29] Canedo, T.; Portugal, C.C.; Socodato, R.; Almeida, T.O.; Terceiro, A.F.; Bravo, J.; Silva, A.I.; Magalhães, J.D.; Guerra-Gomes, S.; Oliveira, J.F.; Sousa, N.; Magalhães, A.; Relvas, J.B.; Summavielle, T. Astrocyte-derived TNF and glutamate critically modulate microglia activation by methamphetamine. *Neuropsychopharmacology*, 2021, 46(13), 2358-2370. http://dx.doi.org/10.1038/s41386-021-01139-7 PMID: 34400780
- [30] Shi, S.X.; Li, Y.J.; Shi, K.; Wood, K.; Ducruet, A.F.; Liu, Q. IL (Interleukin)-15 bridges astrocyte-microglia crosstalk and exacerbates brain injury following intracerebral hemorrhage. *Stroke*, 2020, 51(3), 967-974. http://dx.doi.org/10.1161/STROKEAHA.119.028638 PMID: 32019481
- [31] Wang, T.; Sun, Q.; Yang, J.; Wang, G.; Zhao, F.; Chen, Y.; Jin, Y. Reactive astrocytes induced by 2-chloroethanol modulate microglia

- polarization through IL-1β, TNF-α, and iNOS upregulation. *Food Chem. Toxicol.*, **2021**, *157*, 112550. http://dx.doi.org/10.1016/j.fct.2021.112550 PMID: 34517076
- [32] Yoshizaki, S.; Tamaru, T.; Hara, M.; Kijima, K.; Tanaka, M.; Konno, D.; Matsumoto, Y.; Nakashima, Y.; Okada, S. Microglial inflammation after chronic spinal cord injury is enhanced by reactive astrocytes via the fibronectin/β1 integrin pathway. J. Neuroinflammation, 2021, 18(1), 12. http://dx.doi.org/10.1186/s12974-020-02059-x PMID: 33407620
- [33] Rueda-Carrasco, J.; Martin-Bermejo, M.J.; Pereyra, G.; Mateo, M.I.; Borroto, A.; Brosseron, F.; Kummer, M.P.; Schwartz, S.; López-Atalaya, J.P.; Alarcon, B.; Esteve, P.; Heneka, M.T.; Bovolenta, P. SFRP1 modulates astrocyte-to-microglia crosstalk in acute and chronic neuroinflammation. *EMBO Rep.*, 2021, 22(11), e51696. http://dx.doi.org/10.15252/embr.202051696 PMID: 34569685
- [34] Ouali Alami, N.; Schurr, C.; Olde Heuvel, F.; Tang, L.; Li, Q.; Tasdogan, A.; Kimbara, A.; Nettekoven, M.; Ottaviani, G.; Raposo, C.; Röver, S.; Rogers-Evans, M.; Rothenhäusler, B.; Ullmer, C.; Fingerle, J.; Grether, U.; Knuesel, I.; Boeckers, T.M.; Ludolph, A.; Wirth, T.; Roselli, F.; Baumann, B. NF-κB activation in astrocytes drives a stage-specific beneficial neuroimmunological response in ALS. *EMBO J.*, 2018, 37(16), e98697. http://dx.doi.org/10.15252/embj.201798697 PMID: 29875132
- [35] Kano, S.; Choi, E.Y.; Dohi, E.; Agarwal, S.; Chang, D.J.; Wilson, A.M.; Lo, B.D.; Rose, I.V.L.; Gonzalez, S.; Imai, T.; Sawa, A. Glutathione S -transferases promote proinflammatory astrocytemicroglia communication during brain inflammation. Sci. Signal., 2019, 12(569), eaar2124. http://dx.doi.org/10.1126/scisignal.aar2124 PMID: 30783009
- [36] Li, J.; Wang, H.; Du, C.; Jin, X.; Geng, Y.; Han, B.; Ma, Q.; Li, Q.; Wang, Q.; Guo, Y.; Wang, M.; Yan, B. hUC-MSCs ameliorated CUMS-induced depression by modulating complement C3 signal-ing-mediated microglial polarization during astrocyte-microglia crosstalk. *Brain Res. Bull.*, 2020, 163, 109-119. http://dx.doi.org/10.1016/j.brainresbull.2020.07.004 PMID: 32681971
- [37] Chen, T.; Lennon, V.A.; Liu, Y.U.; Bosco, D.B.; Li, Y.; Yi, M.H.; Zhu, J.; Wei, S.; Wu, L.J. Astrocyte-microglia interaction drives evolving neuromyelitis optica lesion. *J. Clin. Invest.*, 2020, 130(8), 10.1172/JCI134816. http://dx.doi.org/10.1172/JCI134816 PMID: 32568214
- [38] Lian, H.; Litvinchuk, A.; Chiang, A.C.A.; Aithmitti, N.; Jankowsky, J.L.; Zheng, H. Astrocyte-microglia cross talk through complement activation modulates amyloid pathology in mouse models of Alzheimer's disease. *J. Neurosci.*, 2016, 36(2), 577-589. http://dx.doi.org/10.1523/JNEUROSCI.2117-15.2016 PMID: 26758846
- [39] Tang, J.; Jila, S.; Luo, T.; Zhang, B.; Miao, H.; Feng, H.; Chen, Z.; Zhu, G. C3/C3aR inhibition alleviates GMH-IVH-induced hydrocephalus by preventing microglia-astrocyte interactions in neonatal rats. *Neuropharmacology*, 2022, 205, 108927. http://dx.doi.org/10.1016/j.neuropharm.2021.108927 PMID: 34021820
- [40] Wei, Y.; Chen, T.; Bosco, D.B.; Xie, M.; Zheng, J.; Dheer, A.; Ying, Y.; Wu, Q.; Lennon, V.A.; Wu, L.J. The complement C3-C3AR pathway mediates microglia-astrocyte interaction following status epilepticus. *Glia*, 2021, 69(5), 1155-1169. http://dx.doi.org/10.1002/glia.23955 PMID: 33314324
- [41] Zhang, L.Y.; Pan, J.; Mamtilahun, M.; Zhu, Y.; Wang, L.; Ven-katesh, A.; Shi, R.; Tu, X.; Jin, K.; Wang, Y.; Zhang, Z.; Yang, G.Y. Microglia exacerbate white matter injury via complement C3/C3aR pathway after hypoperfusion. *Theranostics*, 2020, 10(1), 74-90. http://dx.doi.org/10.7150/thno.35841 PMID: 31903107
- [42] Hartmann, K.; Sepulveda-Falla, D.; Rose, I.V.L.; Madore, C.; Muth, C.; Matschke, J.; Butovsky, O.; Liddelow, S.; Glatzel, M.; Krasemann, S. Complement 3⁺-astrocytes are highly abundant in prion diseases, but their abolishment led to an accelerated disease course and early dysregulation of microglia. *Acta Neuropathol. Commun.*, 2019, 7(1), 83. http://dx.doi.org/10.1186/s40478-019-0735-1 PMID: 31118110
- [43] Moinfar, Z.; Zamvil, S.S. Microglia complement astrocytes in neuromyelitis optica. J. Clin. Invest., 2020, 130(8), 3961-3964. PMID: 32568215

- [44] Bhusal, A.; Nam, Y.; Seo, D.; Rahman, M.H.; Hwang, E.M.; Kim, S.C.; Lee, W.H.; Suk, K. Cathelicidin-related antimicrobial peptide promotes neuroinflammation through astrocyte-microglia communication in experimental autoimmune encephalomyelitis. *Glia*, 2022, 70(10), 1902-1926. http://dx.doi.org/10.1002/glia.24227 PMID: 35670184
- [45] McAlpine, C.S.; Park, J.; Griciuc, A.; Kim, E.; Choi, S.H.; Iwamoto, Y.; Kiss, M.G.; Christie, K.A.; Vinegoni, C.; Poller, W.C.; Mindur, J.E.; Chan, C.T.; He, S.; Janssen, H.; Wong, L.P.; Downey, J.; Singh, S., Anzai, A.; Kahles, F.; Jorfi, M.; Feruglio, P.F.; Sadreyev, R.I.; Weissleder, R.; Kleinstiver, B.P.; Nahrendorf, M.; Tanzi, R.E.; Swirski, F.K. Astrocytic interleukin-3 programs microglia and limits Alzheimer's disease. *Nature*, 2021, 595(7869), 701-706.
- http://dx.doi.org/10.1038/s41586-021-03734-6 PMID: 34262178

 [46] He, D.; Xu, H.; Zhang, H.; Tang, R.; Lan, Y.; Xing, R.; Li, S.; Christian, E.; Hou, Y.; Lorello, P.; Caldarone, B.; Ding, J.; Nguyen, L.; Dionne, D.; Thakore, P.; Schnell, A.; Huh, J.R.; Rozenblatt-Rosen, O.; Regev, A.; Kuchroo, V.K. Disruption of the IL-33-ST2-AKT signaling axis impairs neurodevelopment by inhibiting microglial metabolic adaptation and phagocytic function. *Immunity*, 2022, 55(1), 159-173.e9.

 http://dx.doi.org/10.1016/j.immuni.2021.12.001 PMID: 34982959
- [47] Vainchtein, I.D.; Chin, G.; Cho, F.S.; Kelley, K.W.; Miller, J.G.; Chien, E.C.; Liddelow, S.A.; Nguyen, P.T.; Nakao-Inoue, H.; Dorman, L.C.; Akil, O.; Joshita, S.; Barres, B.A.; Paz, J.T.; Molofsky, A.B.; Molofsky, A.V. Astrocyte-derived interleukin-33 promotes microglial synapse engulfment and neural circuit development. *Science*, 2018, 359(6381), 1269-1273. http://dx.doi.org/10.1126/science.aal3589 PMID: 29420261
- [48] Kim, J.H.; Afridi, R.; Han, J.; Jung, H.G.; Kim, S.C.; Hwang, E.M.; Shim, H.S.; Ryu, H.; Choe, Y.; Hoe, H.S.; Suk, K. Gamma subunit of complement component 8 is a neuroinflammation inhibitor. *Brain*, 2021, 144(2), 528-552. http://dx.doi.org/10.1093/brain/awaa425 PMID: 33382892
- [49] Jing, W.; Tuxiu, X.; Xiaobing, L.; Guijun, J.; Lulu, K.; Jie, J.; Lu, Y.; Liying, Z.; Xiaoxing, X.; Jingjun, L. LncRNA GAS5/miR-137 is a hypoxia-responsive axis involved in cardiac arrest and cardio-pulmonary cerebral resuscitation. Front. Immunol., 2022, 12, 790750.
- http://dx.doi.org/10.3389/fimmu.2021.790750 PMID: 35087519

 [50] Long, X.; Yao, X.; Jiang, Q.; Yang, Y.; He, X.; Tian, W.; Zhao, K.; Zhang, H. Astrocyte-derived exosomes enriched with miR-873a-5p inhibit neuroinflammation *via* microglia phenotype modulation after traumatic brain injury. *J. Neuroinflammation*, **2020**, *17*(1), 89. http://dx.doi.org/10.1186/s12974-020-01761-0 PMID: 32192523
- [51] Rostami, J.; Mothes, T.; Kolahdouzan, M.; Eriksson, O.; Moslem, M.; Bergström, J.; Ingelsson, M.; O'Callaghan, P.; Healy, L.M.; Falk, A.; Erlandsson, A. Crosstalk between astrocytes and microglia results in increased degradation of α-synuclein and amyloid-β aggregates. *J. Neuroinflammation*, 2021, 18(1), 124. http://dx.doi.org/10.1186/s12974-021-02158-3 PMID: 34082772
- [52] Pekna, M.; Pekny, M. The complement system: A powerful modulator and effector of astrocyte function in the healthy and diseased central nervous system. *Cells*, 2021, 10(7), 1812. http://dx.doi.org/10.3390/cells10071812 PMID: 34359981
- [53] Peng, A.Y.T.; Agrawal, I.; Ho, W.Y.; Yen, Y.C.; Pinter, A.J.; Liu, J.; Phua, Q.X.C.; Koh, K.B.; Chang, J.C.; Sanford, E.; Man, J.H.K.; Wong, P.; Gutmann, D.H.; Tucker-Kellogg, G.; Ling, S.C. Loss of TDP-43 in astrocytes leads to motor deficits by triggering A1-like reactive phenotype and triglial dysfunction. *Proc. Natl. Acad. Sci. USA*, 2020, 117(46), 29101-29112. http://dx.doi.org/10.1073/pnas.2007806117 PMID: 33127758
- [54] Zhang, M.; Liang, W.; Gong, W.; Yoshimura, T.; Chen, K.; Wang, J.M. The critical role of the antimicrobial peptide LL-37/ CRAMP in protection of colon microbiota balance, mucosal homeostasis, anti-inflammatory responses, and resistance to carcinogenesis. *Crit. Rev. Immunol.*, 2019, 39(2), 83-92. http://dx.doi.org/10.1615/CritRevImmunol.2019030225 PMID: 31679249
- [55] Xu, X.; Cai, X.; Zhu, Y.; He, W.; Wu, Q.; Shi, X.; Fang, Y.; Pei, Z. MFG-E8 inhibits Aβ-induced microglial production of cathelicidinrelated antimicrobial peptide: A suitable target against Alzheimer's disease. Cell. Immunol., 2018, 331, 59-66.

[56]

- http://dx.doi.org/10.1016/j.cellimm.2018.05.008 PMID: 29861070 Dörr, A.; Kress, E.; Podschun, R.; Pufe, T.; Tauber, S.C.; Brandenburg, L.O. Intrathecal application of the antimicrobial peptide
- CRAMP reduced mortality and neuroinflammation in an experimental model of pneumococcal meningitis. *J. Infect.*, **2015**, *71*(2), 188-199.
 - http://dx.doi.org/10.1016/j.jinf.2015.04.006 PMID: 25896094
- [57] Lee, M.; Shi, X.; Barron, A.E.; McGeer, E.; McGeer, P.L. Human antimicrobial peptide LL-37 induces glial-mediated neuroinflammation. *Biochem. Pharmacol.*, 2015, 94(2), 130-141. http://dx.doi.org/10.1016/j.bcp.2015.02.003 PMID: 25686659
- [58] Brandenburg, L.O.; Varoga, D.; Nicolaeva, N.; Leib, S.L.; Podschun, R.; Wruck, C.J.; Wilms, H.; Lucius, R.; Pufe, T. Expression and regulation of antimicrobial peptide rCRAMP after bacterial infection in primary rat meningeal cells. *J. Neuroimmunol.*, 2009, 217(1-2), 55-64.
- http://dx.doi.org/10.1016/j.jneuroim.2009.10.004 PMID: 19879657

 [59] Brandenburg, L.O.; Varoga, D.; Nicolaeva, N.; Leib, S.L.; Wilms, H.; Podschun, R.; Wruck, C.J.; Schröder, J.M.; Pufe, T.; Lucius, R. Role of glial cells in the functional expression of LL-37/rat cathelin-related antimicrobial peptide in meningitis. *J. Neuropathol. Exp. Neurol.*, 2008, 67(11), 1041-1054.

 http://dx.doi.org/10.1097/NEN.0b013e31818b4801 PMID: 18957897
- [60] Bergman, P.; Termén, S.; Johansson, L.; Nyström, L.; Arenas, E.; Jonsson, A.B.; Hökfelt, T.; Gudmundsson, G.H.; Agerberth, B. The antimicrobial peptide rCRAMP is present in the central nervous system of the rat. *J. Neurochem.*, **2005**, *93*(5), 1132-1140. http://dx.doi.org/10.1111/j.1471-4159.2005.03081.x PMID: 15934934
- [61] Kress, E.; Merres, J.; Albrecht, L.J.; Hammerschmidt, S.; Pufe, T.; Tauber, S.C.; Brandenburg, L.O. CRAMP deficiency leads to a pro-inflammatory phenotype and impaired phagocytosis after exposure to bacterial meningitis pathogens. *Cell Commun. Signal.*, 2017, 15(1), 32. http://dx.doi.org/10.1186/s12964-017-0190-1 PMID: 28915816
- [62] Smith, K.J.; Minns, D.; McHugh, B.J.; Holloway, R.K.; O'Connor, R.; Williams, A.; Melrose, L.; McPherson, R.; Miron, V.E.; Davidson, D.J.; Findlay, E.G. The antimicrobial peptide cathelicidin is critical for the development of Th17 responses in severe inflammatory disease. bioRxiv, 2022, 2022.2001.2027.477976. http://dx.doi.org/10.1101/2022.01.27.477976
- [63] Komuczki, J.; Tuzlak, S.; Friebel, E.; Hartwig, T.; Spath, S.; Rosenstiel, P.; Waisman, A.; Opitz, L.; Oukka, M.; Schreiner, B.; Pelczar, P.; Becher, B. Fate-Mapping of GM-CSF expression identifies a discrete subset of inflammation-driving T helper cells regulated by cytokines IL-23 and IL-1β. *Immunity*, 2019, 50(5), 1289-1304.e6. http://dx.doi.org/10.1016/j.immuni.2019.04.006 PMID: 31079916
- [64] Dokalis, N.; Prinz, M. Astrocytic NF-κB brings the best and worst out of microglia. EMBO J., 2018, 37(16), e100130. http://dx.doi.org/10.15252/embj.2018100130 PMID: 30037825
- [65] Barbosa, M.; Gomes, C.; Sequeira, C.; Gonçalves-Ribeiro, J.; Pina, C.C.; Carvalho, L.A.; Moreira, R.; Vaz, S.H.; Vaz, A.R.; Brites, D. Recovery of depleted miR-146a in ALS cortical astrocytes reverts cell aberrancies and prevents paracrine pathogenicity on microglia and motor neurons. Front. Cell Dev. Biol., 2021, 9, 634355. http://dx.doi.org/10.3389/fcell.2021.634355 PMID: 33968923
- [66] Negahdaripour, M.; Owji, H.; Eskandari, S.; Zamani, M.; Vakili, B.; Nezafat, N. Small extracellular vesicles (sEVs): Discovery, functions, applications, detection methods and various engineered forms. Expert Opin. Biol. Ther., 2021, 21(3), 371-394.
- http://dx.doi.org/10.1080/14712598.2021.1825677 PMID: 32945228 Zhu, S-X.; Zhou, S-L.; Xie, H-M.; Su, X.; Zhang, F-Y.; Dai, C-L.; Wu, R-H.; Li, Y.; Han, X-X.; Feng, X-M.; Yu, B. Profile of the RNA in exosomes from astrocytes and microglia using deep sequencing: Implications for neurodegeneration mechanisms. *Neural Regen. Res.*, 2022, 17(3), 608-617. http://dx.doi.org/10.4103/1673-5374.320999 PMID: 34380901

- [68] Wang, J.; Ma, P.; Kim, D.H.; Liu, B.F.; Demirci, U. Towards microfluidic-based exosome isolation and detection for tumor therapy. *Nano Today*, 2021, 37, 101066. http://dx.doi.org/10.1016/j.nantod.2020.101066 PMID: 33777166
- [69] Witwer, K.W.; Théry, C. Extracellular vesicles or exosomes? On primacy, precision, and popularity influencing a choice of nomenclature. *J. Extracell. Vesicles*, 2019, 8(1), 1648167. http://dx.doi.org/10.1080/20013078.2019.1648167 PMID: 31489144
- [70] Pei, X.; Li, Y.; Zhu, L.; Zhou, Z. Astrocyte-derived exosomes suppress autophagy and ameliorate neuronal damage in experimental ischemic stroke. *Exp. Cell Res.*, 2019, 382(2), 111474. http://dx.doi.org/10.1016/j.yexcr.2019.06.019 PMID: 31229506
- [71] Xu, L.; Cao, H.; Xie, Y.; Zhang, Y.; Du, M.; Xu, X.; Ye, R.; Liu, X. Exosome-shuttled miR-92b-3p from ischemic preconditioned astrocytes protects neurons against oxygen and glucose deprivation. *Brain Res.*, 2019, 1717, 66-73.
- http://dx.doi.org/10.1016/j.brainres.2019.04.009 PMID: 30986407

 [72] Rostami, J.; Holmqvist, S.; Lindström, V.; Sigvardson, J.; Westermark, G.T.; Ingelsson, M.; Bergström, J.; Roybon, L.; Erlandsson, A. Human astrocytes transfer aggregated alpha-synuclein via tunneling nanotubes. J. Neurosci., 2017, 37(49), 11835-11853. http://dx.doi.org/10.1523/JNEUROSCI.0983-17.2017 PMID: 29089438
- [73] Lana, D.; Ugolini, F.; Wenk, G.L.; Giovannini, M.G.; Zecchi-Orlandini, S.; Nosi, D. Microglial distribution, branching, and clearance activity in aged rat hippocampus are affected by astrocyte meshwork integrity: Evidence of a novel cell-cell interglial interaction. *FASEB J.*, 2019, 33(3), 4007-4020. http://dx.doi.org/10.1096/fj.201801539R PMID: 30496700
- [74] Kim, S.; Steelman, A.J.; Koito, H.; Li, J. Astrocytes promote TNF-mediated toxicity to oligodendrocyte precursors. *J. Neurochem.*, 2011, 116(1), 53-66. http://dx.doi.org/10.1111/j.1471-4159.2010.07084.x PMID: 21044081
- [75] Kraft, A.D.; McPherson, C.A.; Harry, G.J. Heterogeneity of microglia and TNF signaling as determinants for neuronal death or survival. *Neurotoxicology*, 2009, 30(5), 785-793. http://dx.doi.org/10.1016/j.neuro.2009.07.001 PMID: 19596372
- [76] Song, J.H.; Bellail, A.; Tse, M.C.; Yong, V.W.; Hao, C. Human astrocytes are resistant to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. *J. Neurosci.*, 2006, 26(12), 3299-3308. http://dx.doi.org/10.1523/JNEUROSCI.5572-05.2006 PMID: 16554480
- [77] Dietrich, P.Y.; Walker, P.R.; Saas, P. Death receptors on reactive astrocytes. *Neurology*, 2003, 60(4), 548-554. http://dx.doi.org/10.1212/01.WNL.0000042049.74547.7F PMID: 12607528
- [78] Lee, S.J.; Zhou, T.; Choi, C.; Wang, Z.; Benveniste, E.N. Differential regulation and function of Fas expression on glial cells. *J. Immunol.*, 2000, 164(3), 1277-1285. http://dx.doi.org/10.4049/jimmunol.164.3.1277 PMID: 10640741
- [79] Polyzos, A.A.; Lee, D.Y.; Datta, R.; Hauser, M.; Budworth, H.; Holt, A.; Mihalik, S.; Goldschmidt, P.; Frankel, K.; Trego, K.; Bennett, M.J.; Vockley, J.; Xu, K.; Gratton, E.; McMurray, C.T. Metabolic reprogramming in astrocytes distinguishes region-specific neuronal susceptibility in huntington mice. *Cell Metab.*, 2019, 29(6), 1258-1273.e11. http://dx.doi.org/10.1016/j.cmet.2019.03.004 PMID: 30930170
- [80] Garland, E.F.; Hartnell, I.J.; Boche, D. Microglia and astrocyte function and communication: What do we know in humans? Front. Neurosci., 2022, 16, 824888. http://dx.doi.org/10.3389/fnins.2022.824888 PMID: 35250459
- [81] Lanjewar, S.N.; Sloan, S.A. Growing Glia: Cultivating human stem cell models of gliogenesis in health and disease. *Front. Cell Dev. Biol.*, 2021, 9, 649538. http://dx.doi.org/10.3389/fcell.2021.649538 PMID: 33842475